PML is an inclusion criterion in 6 clinical trials for acute promyelocytic leukemia, of which 3 are open and 3 are closed. Of the trials that contain PML status and acute promyelocytic leukemia as inclusion criteria, 2 are phase 1 (0 open), 2 are phase 2 (1 open), and 2 are phase 3 (2 open) [4].

Arsenic trioxide has evidence of efficacy in patients with PML mutation in acute promyelocytic leukemia [4].

PML is altered in 4.02% of acute myeloid leukemia patients [3].

PML is an inclusion criterion in 34 clinical trials for acute myeloid leukemia, of which 15 are open and 19 are closed. Of the trials that contain PML status and acute myeloid leukemia as inclusion criteria, 12 are phase 1 (5 open), 6 are phase 1/phase 2 (2 open), 7 are phase 2 (2 open), 2 are phase 2/phase 3 (2 open), 3 are phase 3 (2 open), and 4 are no phase specified (2 open) [4].

PML is an inclusion criterion in 6 clinical trials for myelodysplastic syndromes, of which 3 are open and 3 are closed. Of the trials that contain PML status and myelodysplastic syndromes as inclusion criteria, 4 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (0 open) [4].

PML is an inclusion criterion in 2 clinical trials for acute lymphoblastic leukemia, of which 1 is open and 1 is closed. Of the trials that contain PML status and acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (0 open) [4].

PML is an inclusion criterion in 2 clinical trials for chronic lymphocytic leukemia, of which 0 are open and 2 are closed. Of the trials that contain PML status and chronic lymphocytic leukemia as inclusion criteria, 1 is phase 1/phase 2 (0 open) and 1 is phase 3 (0 open) [4].

PML is altered in 5.88% of mantle cell lymphoma patients [3].

PML is an inclusion criterion in 1 clinical trial for mantle cell lymphoma, of which 0 are open and 1 is closed. Of the trial that contains PML status and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [4].

PML is an inclusion criterion in 1 clinical trial for atypical chronic myeloid leukemia, BCR-ABL1 negative, of which 0 are open and 1 is closed. Of the trial that contains PML status and atypical chronic myeloid leukemia, BCR-ABL1 negative as inclusion criteria, 1 is no phase specified (0 open) [4].

PML is an inclusion criterion in 1 clinical trial for chronic myelomonocytic leukemia, of which 0 are open and 1 is closed. Of the trial that contains PML status and chronic myelomonocytic leukemia as inclusion criteria, 1 is phase 1 (0 open) [4].

PML is an inclusion criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains PML status and multiple myeloma as inclusion criteria, 1 is phase 1 (1 open) [4].

PML is an inclusion criterion in 1 clinical trial for myelodysplastic/myeloproliferative neoplasm, of which 0 are open and 1 is closed. Of the trial that contains PML status and myelodysplastic/myeloproliferative neoplasm as inclusion criteria, 1 is phase 1 (0 open) [4].

PML is an inclusion criterion in 1 clinical trial for myeloproliferative neoplasm, of which 0 are open and 1 is closed. Of the trial that contains PML status and myeloproliferative neoplasm as inclusion criteria, 1 is phase 2 (0 open) [4].

PML is an inclusion criterion in 1 clinical trial for refractory anemia with excess blasts, of which 0 are open and 1 is closed. Of the trial that contains PML status and refractory anemia with excess blasts as inclusion criteria, 1 is phase 1 (0 open) [4].